Interested in the improvement of medication for hidradenitis suppurativa (HS)? We’ve scanned the latest reports and summarized them for you here in our 2025 Q2 HS research update.
Off-Label Ixekizumab After Humira Failure
May 5, 2025
In a small study of just 10 HS patients, ixekizumab (Taltz) was evaluated as a potential medication for HS after Humira stopped working.
Seven patients reported fewer inflammatory lesions, and five achieved a 55% reduction in their HS severity score. While promising, the trial was small and informal more research is needed to determine if Taltz could become a reliable addition to available HS medications.
Read more
Zura Bio Launches Phase 2 TibuSHIELD Study
May 20, 2025
A global clinical trial has begun to evaluate Tibulizumab in adults with HS. TibuSHIELD combines the autoimmune medication Taltz with tabalumab, targeting both the IL-17A pathway and B-cell activating factor (BAFF). Researchers hope this dual approach may offer a stronger medication for HS, with results expected in Q3 2026.
Read more
Navigator Medicines Doses First Participants in NAV-240 Trial
May 29, 2025
Navigator Medicines has begun a Phase 1b trial of NAV-240, a next-generation antibody drug designed to block two major drivers of inflammation (TNFα and OX40L). For patients with HS, this could represent a new class of HS medications capable of longer-lasting relief compared to single-target drugs. Interim results are expected by the end of 2025, with NAV-240 and its partner NAV-242 also being developed for Crohn’s disease and ulcerative colitis.
Read more
Conclusion
That’s it for now—three promising new developments in the search for HS medications that can deliver more reliable relief for patients living with hidradenitis suppurativa.
If you want to help us make a change in how HS is treated we are recruiting participants for clinical research trials for HS. Follow the link in orange or call us at (289)-763-8666
Disclaimer
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for personal guidance.
